In recent trials, patients with HER2+ breast cancer (BC) have been reported as deriving clinically meaningful benefits from subsequent administration of HER2 inhibitors, such as lapatinib, pertuzumab, and T-DM1. This evidence concerns the gene ERBB2 and breast carcinoma.